Evinature

Evinature is a science-first nutraceutical company tackling unmet needs in gastrointestinal health.

Health Tech & Life Sciences
Active
Seed Binyamina-Giv'at Ada, Israel Founded 2021
Last updated 2026-07-26
Total raised
$6.5M
Last: Undisclosed Round 2024-02
Stage
Seed
Founded
2021
Headcount
17
HQ
Binyamina-Giv'at Ada, Israel
Sector
Health Tech & Life Sciences

About

Evinature combines modern science and traditional botanical knowledge to offer natural, well-researched solutions for gut health. The company focuses on developing, evaluating, and refining its formulas through ongoing research and collaborations with leading medical centers. Evinature provides personalized guidance and ongoing digital check-ins to support individual wellness goals, with a commitment to evidence-based protocols and transparent information. Their products are designed to support digestive health and help individuals manage chronic bowel challenges, starting with Inflammatory Bowel Disease (IBD).

Funding history · 3 rounds · $6.5M total

2024-01
Seed Extension $2.5M
2023-09
Seed $2.0M
2022-05
Pre-Seed $2.0M
★ Ratio Technologies

Headcount over time

From 2 (2022-01) to 19 (2026-03) · +17 (+850%) · 19 points · source: Finder history + radar grounding
190 2022-01 2026-03

Q&A

What is Evinature's primary focus?
Evinature is a science-first nutraceutical company dedicated to addressing unmet needs in gastrointestinal health, particularly Inflammatory Bowel Disease (IBD).
When was Evinature founded?
Evinature was founded in April 2021.
What is Evinature's employee count?
Evinature has 11-50 employees.
What is the total amount of funding Evinature has raised?
Evinature has raised a total of $6.5 million USD.
When was Evinature's most recent funding round?
Evinature completed a Seed funding round in February 2024, raising $2.5 million USD.
Which investor participated in Evinature's Pre-Seed round?
Ratio Technologies participated in Evinature's Pre-Seed funding round in June 2022.
Who are the founders of Evinature?
The founders of Evinature are Apan Amos Damri (CEO), Prof. Shomron Ben-Horin M.D. (Co-founder & Chief Medical Officer), and Nir Salomon (Co-founder & Head of R&D).
In which sector does Evinature primarily operate?
Evinature's primary sector is Health Tech & Life Sciences.
What is Evinature's product stage?
Evinature's products are currently released.
Has Evinature been recognized in any recent industry reports?
Yes, in July 2024, Evinature was listed among the most-watched Health Tech companies in Startup Nation's H1 2024 Israeli Tech Report.

Team · 3

Apan Amos Damri
Founder · Founder, CEO
Prof. Shomron Ben-Horin M.D.
Founder · Co-founder & Chief Medical Officer
Nir Salomon
Founder · Co-founder & Head of R&D

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsHerbals
Target customers
Healthcare & Life SciencesHealthcarePatients
Business model
B2BB2B2CB2C

Highlights

1 PatentsVerified

Tags

supplementsmedical-productsmental-healthpharmaceuticalsgastroenterologytreatmentsinflammatory-diseasescrohn-s-diseasenutraceuticals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteevinature.com/
LinkedInlinkedin.com/company/79820201
Facebookfacebook.com/evinature
YouTubeyoutube.com/@Evinature
Instagraminstagram.com/evinature

Identifiers & details

Legal nameEVINATURE LTD
Founded2021-4
Employees (exact)17

Radar intelligence

Patents

EPO2

Publications (Crossref)

Works1

Web history (Wayback)

Domainevinature.com

Certificate / subdomain footprint

Subdomains14

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)516384070
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2021-04-25
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)no
Last annual report2025
Active charges / liens0
Registry events2 — shares_capital (1), annual_report (1)
Registered addressהמלאכה 3 בנימינה

Recent registry events

DateEvent
2026-05-28הקצאת מניות
2025-09-03דו~ח שנתי-הוספת בעל תפקיד